Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

117 results about "Genome engineering" patented technology

Genome engineering refers to the strategies and techniques developed in recent years for the targeted, specific modification of the genetic information – or genome – of living organisms. It represents a very active field of research because of the wide range of possible applications, particularly in the areas of human health - the correction of a gene carrying a harmful mutation, the production of therapeutic proteins, the elimination of persistent viral sequences - agricultural biotechnology - the development of new generations of genetically modified plants - and for the development of research tools - for example, to explore the function of a gene. Early technologies developed to insert a gene into a living cell, such as transgenesis, are limited by the random nature of the insertion of the new sequence into the genome. The new gene is positioned blindly, and may inactivate or disturb the functioning of other genes or even cause severe unwanted effects; it may trigger a process of cancerization, for example. Furthermore, these technologies offer no degree of reproducibility, as there is no guarantee that the new sequence will be inserted at the same place in two different cells.

Meganuclease variants cleaving a DNA target sequence from the dystrophin gene and uses thereof

InactiveUS20130145487A1Expression is sufficient and stableNo impact on the expression of other genesSugar derivativesBacteriaA-DNANuclease
The invention relates to meganuclease variants which cleave a DNA target sequence from the human dystrophin gene (DMD), to vectors encoding such variants, to a cell, an animal or a plant modified by such vectors and to the use of these meganuclease variants and products derived therefrom for genome therapy, ex vivo (gene cell therapy) and genome engineering including therapeutic applications and cell line engineering. The invention also relates to the use of meganuclease variants for inserting therapeutic transgenes other than DMD at the dystrophin gene locus, using this locus as a safe harbor locus. The invention also relates to the use of meganuclease variants for using the dystrophin gene locus as a landing pad to insert and express genes of interest.
Owner:CELLECTIS SA

Method for increasing the efficiency of double-strand break-induced mutagenesis

InactiveUS20130337454A1Increasing double-strand break-induced mutagenesisPreventing any scarless re-ligationSugar derivativesHydrolasesGeneticsDouble stranded
The present invention relates to a method for increasing double-strand break-induced mutagenesis at a genomic locus of interest in a cell, thereby giving new tools for genome engineering, including therapeutic applications and cell line engineering. More specifically, the present invention concerns a method for increasing double-strand break-induced mutagenesis at a genomic locus of interest, leading to a loss of genetic information and preventing any scarless re-ligation of said genomic locus of interest by NHEJ. The present invention also relates to engineered endonucleases, chimeric or not, vectors, compositions and kits used to implement this method.
Owner:CELLECTIS SA

Method for increasing the efficiency of double-strand-break induced mutagenesis

The present invention relates to a method for increasing double-strand-break induced mutagenesis at a genomic locus of interest in a cell, thereby giving new tools for genome engineering, including therapeutic applications and cell line engineering. More specifically, the present invention concerns the combined use of TALEN or meganucleases with TREX2, especially under the form of single-chain proteins.
Owner:CELLECTIS SA

Novel mitochondrial genome editing tool

The present invention discloses a novel mitochondrial genome editing tool, and belongs to the field of genome engineering. According to the prevent invention, the constructed mtCRISPR / Cas9 system mainly comprises two parts such as gRNA entering mitochondria and Cas9 nuclease localized in mitochondria, wherein the constructed mt-gRNA has two forms, the one mt-gRNA comprises a RNA mitochondrial localizing guide sequence, a targeting sequence and a gRNA skeleton sequence, the other mt-gRNA comprises a RNA mitochondrial localizing guide sequence, any one tRNA sequence encoded by mitochondrial or other additional spacer sequences, a targeting sequence and a gRNA skeleton sequence, the obtained combined material acts on the mitochondrial genome to break the target sequence in a targeted manner after the mt-gRNA and the mtCas9 nuclease are combined, and the action efficiency of the second mt-gRNA action is high than the action efficiency of the mt-gRNA; and the results verify that the constructed mtCRISPR / Cas9 system has characteristics of high efficiency and strong specificity.
Owner:聂凌云

Methods for increasing cas9-mediated engineering efficiency

Methods for use with Type II CRISPR-Cas9 systems for increasing Cas9-mediated genome engineering efficiency are disclosed. The methods can be used to decrease the number of off-target nucleic acid double-stranded breaks and / or to enhance homology-directed repair of a cleaved target nucleic acid.
Owner:CARIBOU BIOSCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products